Hemophilia management continues to evolve as new classes of prophylactic therapy become available. Emicizumab, a novel bispecific antibody substitutive therapy, is the first non-factor replacement therapy licensed for prophylaxis for individuals with hemophilia A with or without FVIII inhibitors of all ages.

This session contrasts the potential for favorable clinical and patient outcomes when incorporating emicizumab into patient management with the potential consequences focusing on specific hemophilia A subgroups. Speakers will highlight current data, considerations for clinical decision-making, and gaps in available information in a number of clinical situations including: previously untreated patients (PUPs), managing new FVIII inhibitors patients and immune tolerance induction, peri-surgical management, non-severe hemophilia, and the aging hemophilia population.